Toviaz approved for overactive bladder.
作者信息
Traynor Kate
出版信息
Am J Health Syst Pharm. 2008 Dec 1;65(23):2184. doi: 10.2146/news080091.
PMID:19020177
Abstract
摘要
相似文献
1
Toviaz approved for overactive bladder.
Am J Health Syst Pharm. 2008 Dec 1;65(23):2184. doi: 10.2146/news080091.
2
Fesoterodine (toviaz) for overactive bladder.
Med Lett Drugs Ther. 2009 May 4;51(1311):34-5.
3
New drug information: Toviaz.
JAAPA. 2009 Jun;22(6):12.
4
Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.特托罗定治疗老年和年轻膀胱过度活动症患者的疗效和耐受性。
Urology. 2010 Dec;76(6):1350-7. doi: 10.1016/j.urology.2010.03.097. Epub 2010 Oct 25.
5
FDA approval signals more 'homework' on the horizon in trials.美国食品药品监督管理局的批准意味着在试验方面即将有更多“功课”要做。
Nat Med. 2011 Jul 7;17(7):754. doi: 10.1038/nm0711-754b.
6
Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.特托罗定治疗膀胱过度活动症患者的长期安全性、耐受性和疗效。
Int J Clin Pract. 2010 Apr;64(5):584-93. doi: 10.1111/j.1742-1241.2010.02361.x. Epub 2010 Feb 19.
7
Early onset of fesoterodine efficacy in subjects with overactive bladder.特索罗定早期疗效在膀胱过度活动症患者中的体现。
BJU Int. 2011 Feb;107(4):598-602. doi: 10.1111/j.1464-410X.2010.09586.x. Epub 2010 Sep 24.
8
Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
J Urol. 2006 Nov;176(5):2311-2; author reply 2312-3. doi: 10.1016/j.juro.2006.06.053.
9
Thorough QT study with recommended and supratherapeutic doses of tolterodine.使用推荐剂量和超治疗剂量的托特罗定进行全面的QT研究。
Clin Pharmacol Ther. 2008 Feb;83(2):231-2; author reply 233. doi: 10.1038/sj.clpt.6100328.
10
Tolterodine for the treatment of overactive bladder.托特罗定用于治疗膀胱过度活动症。
Expert Opin Pharmacother. 2008 May;9(7):1249-55. doi: 10.1517/14656566.9.7.1249.
Zotero 插件